NETs Get Real with NCAN June 2025 Livestream Encore Presentation with Dr. James Howe!
25 snips
Jul 2, 2025 Dr. James Howe, a surgical oncologist at the University of Iowa, shares insights on neuroendocrine tumors and the vital role of mentorship in his field. He discusses the MEN1 genetic test for assessing cancer risk and the intricacies of diagnosing small bowel tumors. The conversation shifts to histotripsy as a non-invasive treatment for liver lesions and highlights advancements in PRRT for neuroendocrine tumors, emphasizing personalized treatment strategies. Howe also addresses patient concerns about medication transitions and the challenges of participating in clinical trials.
AI Snips
Chapters
Transcript
Episode notes
Dr. Howe's NET Journey
- Dr. James Howe began working with NET patients through patient mentors Tom and Sue Odoricio at the University of Iowa in 1999.
- Over decades, he developed multidisciplinary care expertise for small bowel and pancreatic neuroendocrine tumors and their liver metastases.
When to Get MEN1 Testing
- MEN1 genetic testing is recommended for patients with pancreatic neuroendocrine tumors and a family history of MEN1-related conditions.
- Consult a genetic counselor to evaluate family history and discuss pros and cons before testing.
Understanding the NET Test
- The NET test is an RNA-based proprietary assay aiming to detect recurrence more sensitively than chromogranin.
- Imaging confirmation remains essential before changing treatment based on test results alone.